Stock Research for GSK

GSK

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

GSK Stock Chart & Research Data

The GSK chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GSK chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


GSK Due diligence Resources & Stock Charts

The GSK stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GSK Detailed Price Forecast - CNN Money CNN View GSK Detailed Summary - Google Finance
Yahoo View GSK Detailed Summary - Yahoo! Finance Zacks View GSK Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View GSK Trends & Analysis - Trade-Ideas Barrons View GSK Major Holders - Barrons
NASDAQ View GSK Call Transcripts - NASDAQ Seeking View GSK Breaking News & Analysis - Seeking Alpha
Spotlight View GSK Annual Report - CompanySpotlight.com OTC Report View GSK OTC Short Report - OTCShortReport.com
TradeKing View GSK Fundamentals - TradeKing Charts View GSK SEC Filings - Bar Chart
WSJ View Historical Prices for GSK - The WSJ Morningstar View Performance/Total Return for GSK - Morningstar
MarketWatch View the Analyst Estimates for GSK - MarketWatch CNBC View the Earnings History for GSK - CNBC
StockMarketWatch View the GSK Earnings - StockMarketWatch MacroAxis View GSK Buy or Sell Recommendations - MacroAxis
Bullish View the GSK Bullish Patterns - American Bulls Short Pains View GSK Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View GSK Stock Mentions - StockTwits PennyStocks View GSK Stock Mentions - PennyStockTweets
Twitter View GSK Stock Mentions - Twitter Invest Hub View GSK Investment Forum News - Investor Hub
Yahoo View GSK Stock Mentions - Yahoo! Message Board Seeking Alpha View GSK Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for GSK - SECform4.com Insider Cow View Insider Transactions for GSK - Insider Cow
CNBC View GSK Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GSK - OTC Markets
Yahoo View Insider Transactions for GSK - Yahoo! Finance NASDAQ View Institutional Holdings for GSK - NASDAQ


Stock Charts

FinViz View GSK Stock Insight & Charts - FinViz.com StockCharts View GSK Investment Charts - StockCharts.com
BarChart View GSK Stock Overview & Charts - BarChart Trading View View GSK User Generated Charts - Trading View




Latest Financial News for GSK


10 Best Weight Loss Drug Stocks to Buy Now
Posted on Saturday April 06, 2024

In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]


Health Care Roundup: Market Talk
Posted on Friday April 05, 2024

Read about Agilent Technologies, Novartis, Master Style and more in the latest Market Talks covering the Health Care sector.


GSK PLC Sponsored ADR (GSK) is Attracting Investor Attention: Here is What You Should Know
Posted on Thursday March 28, 2024

Recently, Zacks.com users have been paying close attention to Glaxo (GSK). This makes it worthwhile to examine what the stock has in store.


UPDATE 1-U.S. FDA approves Akebia's anemia drug
Posted on Wednesday March 27, 2024

The U.S. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday. The FDA had earlier declined to approve vadadustat - a Hypoxia-inducible factor–prolyl hydroxylase (HIF-PH) inhibitor - on safety concerns, as it posed an increased risk of blood clot formations and drug-induced injuries to the liver.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.